正在加载视频...

视频加载失败

返回首页

🚨 SHOCKING BOMBSHELL: They’ve been hiding this from you. Dr. Peter McCullough just exposed it in this video: A new real-world study of 197 cancer patients treated with low-dose Ivermectin (25 mg) + Mebendazole (250 mg). After just 6 months: 84.4% had clinical benefit 48.4% had tumor reduction or...

DawnsMission's profile picture

Dr. Dawn Michael

227,041 subscribers

116,310 次观看 • 2 个月前 •via X (Twitter)

健康养生
LIVE

Anya Rossi• Live Now

Private livecam show

0 条评论

暂无评论

原始帖子的评论将显示在这里

相关视频

🚨NEARLY HALF OF CANCER PATIENTS TAKING IVERMECTIN + MEBENDAZOLE REPORTED CANCER DISAPPEARANCE OR TUMOR REGRESSION AFTER 6 MONTHS 84.4% EXPERIENCED CLINICAL BENEFIT 32.8% REPORTED NO EVIDENCE OF DISEASE 15.6% REPORTED TUMOR REGRESSION 36.1% REPORTED STABLE DISEASE Our study represents the largest and most compelling clinical signal to date supporting antiparasitic therapy in cancer. McCullough Foundation The Wellness Company Peter A. McCullough, MD, MPH® Harvey Risch Kelly Victory MD James Thorp MD Dr. Drew Peter Gillooly Foster Coulson
1:34

🚨NEARLY HALF OF CANCER PATIENTS TAKING IVERMECTIN + MEBENDAZOLE REPORTED CANCER DISAPPEARANCE OR TUMOR REGRESSION AFTER 6 MONTHS 84.4% EXPERIENCED CLINICAL BENEFIT 32.8% REPORTED NO EVIDENCE OF DISEASE 15.6% REPORTED TUMOR REGRESSION 36.1% REPORTED STABLE DISEASE Our study represents the largest and most compelling clinical signal to date supporting antiparasitic therapy in cancer. McCullough Foundation The Wellness Company Peter A. McCullough, MD, MPH® Harvey Risch Kelly Victory MD James Thorp MD Dr. Drew Peter Gillooly Foster Coulson

Nicolas Hulscher, MPH

764,092 次观看 • 5 个月前

🚨 CANCER PATIENTS — THESE RESULTS DESERVE SERIOUS ATTENTION Dr. Diaz describes what he says is the largest study to date examining ivermectin and mebendazole together in cancer patients. 197 patients. Six months. Used alongside other conventional interventions. According to Dr. Diaz: 84.4% showed clinical benefit. 32.8% showed no evidence of disease. 15.6% experienced tumour regression. Those are extraordinary reported results. If they withstand rigorous scrutiny, the obvious question is: Why wouldn't we investigate this further — urgently? Cancer touches almost every family. Watch this. Listen to the figures. Then ask whether inexpensive, repurposed medicines are receiving the scientific attention they deserve. The Wellness Company Dr. Alejandro Díaz
1:14

🚨 CANCER PATIENTS — THESE RESULTS DESERVE SERIOUS ATTENTION Dr. Diaz describes what he says is the largest study to date examining ivermectin and mebendazole together in cancer patients. 197 patients. Six months. Used alongside other conventional interventions. According to Dr. Diaz: 84.4% showed clinical benefit. 32.8% showed no evidence of disease. 15.6% experienced tumour regression. Those are extraordinary reported results. If they withstand rigorous scrutiny, the obvious question is: Why wouldn't we investigate this further — urgently? Cancer touches almost every family. Watch this. Listen to the figures. Then ask whether inexpensive, repurposed medicines are receiving the scientific attention they deserve. The Wellness Company Dr. Alejandro Díaz

Jim Ferguson

15,154 次观看 • 29 天前

An infuriated Dr John Campbell says the latest cancer study is remarkable and shows we could be curing the world of cancer with ivermectin/ mebendazole. He breaks it down: • 197 patients took 25mg ivermectin and 250 mg mebendazole daily for 90 days: • 84% had a positive response • only 15.6% had cancer progression • the combination appears to be effective against a very wide range of cancers. ‘It just drives you mad really these studies are crying out to be done’
3:58

An infuriated Dr John Campbell says the latest cancer study is remarkable and shows we could be curing the world of cancer with ivermectin/ mebendazole. He breaks it down: • 197 patients took 25mg ivermectin and 250 mg mebendazole daily for 90 days: • 84% had a positive response • only 15.6% had cancer progression • the combination appears to be effective against a very wide range of cancers. ‘It just drives you mad really these studies are crying out to be done’

Kat A 🌸

195,069 次观看 • 4 个月前

💥BOMBSHELL NEW STUDY: 84.4% Of Cancer Patients Taking Ivermectin & Mebendazole Had Their Cancer Completely Disappear, Shrink, Or Stop Spreading After 6 Months In Massive Peer-Reviewed / Published Real-World Study! PLUS, Neurological Conditions Such As Parkinson's & Alzheimer's Disease Improved By Ivermectin According To Dr. William Makis MD's Treatments / Patient Testimonies! Alex Jones Breaks Down Why This Info Is Scrubbed From The Internet, "Big Pharma Has Gone To Google & Paid Them Billions To Suppress Everything! There Are Thousands Of Incredible Drugs! They Want You To Have The Expensive, Toxic, Bad Ones Because The Drug Companies & Insurance Companies Are Co-Owned- It's All Just A Giant Scam!" 🔴WATCH/SHARE ALEX JONES LIVE NOW:
13:57

💥BOMBSHELL NEW STUDY: 84.4% Of Cancer Patients Taking Ivermectin & Mebendazole Had Their Cancer Completely Disappear, Shrink, Or Stop Spreading After 6 Months In Massive Peer-Reviewed / Published Real-World Study! PLUS, Neurological Conditions Such As Parkinson's & Alzheimer's Disease Improved By Ivermectin According To Dr. William Makis MD's Treatments / Patient Testimonies! Alex Jones Breaks Down Why This Info Is Scrubbed From The Internet, "Big Pharma Has Gone To Google & Paid Them Billions To Suppress Everything! There Are Thousands Of Incredible Drugs! They Want You To Have The Expensive, Toxic, Bad Ones Because The Drug Companies & Insurance Companies Are Co-Owned- It's All Just A Giant Scam!" 🔴WATCH/SHARE ALEX JONES LIVE NOW:

Alex Jones

368,030 次观看 • 27 天前

🚨Dr. William Makis: Ivermectin Dosing for Cancer Explained In one of his recent talks, Dr. William Makis shared what he considers the most important dosing guide for using Ivermectin in cancer. According to Dr. Makis, the starting dose for most cancers is 1 mg per kilogram of body weight per day For example, a person weighing 60 kg would take 60 mg daily, that’s five 12 mg pills or roughly one teaspoon (6 ml) of liquid ivermectin. He mentioned that Ivermectin has shown positive effects in many types of cancer, including: - Breast cancer - Colon cancer - Lung cancer - Pancreatic cancer - Gastric cancer - Renal cell carcinoma - Leukemias He noted that there is very little research on lymphomas, but that doesn’t mean it won’t work, it simply hasn’t been studied much yet. Important points from Dr. Makis: 1) The anti-cancer effect of Ivermectin appears to be dose dependent. 2) Higher doses may offer better results in more aggressive cancers. 3) For very aggressive cancers (such as pancreatic, leukemia, or brain cancers), he suggests considering 2 mg/kg or even up to 2.5 mg/kg per day. Some patients have used these higher doses for many months with only temporary side effects (such as mild visual disturbances that usually resolve within a few days). Real-world examples include a prostate cancer patient whose PSA dropped from 89 to 11 on 45 mg daily, and a terminal gallbladder cancer case that resolved after 14 months on 2 mg/kg. Dr. Makis emphasizes that Ivermectin is a very safe drug with no reported long-term side effects at 1 mg/kg. He recommends starting at this dose and adjusting upwards depending on the individual case and cancer type. He also stresses that people can safely stay on Ivermectin for months as long as there is active disease. If you're researching Ivermectin for cancer protocols, many people are choosing GENIX MEDS for clean, pharmaceutical-grade Ivermectin with straightforward worldwide delivery. #Ivermectindosage #MakisMD #Genixmeds
5:47

🚨Dr. William Makis: Ivermectin Dosing for Cancer Explained In one of his recent talks, Dr. William Makis shared what he considers the most important dosing guide for using Ivermectin in cancer. According to Dr. Makis, the starting dose for most cancers is 1 mg per kilogram of body weight per day For example, a person weighing 60 kg would take 60 mg daily, that’s five 12 mg pills or roughly one teaspoon (6 ml) of liquid ivermectin. He mentioned that Ivermectin has shown positive effects in many types of cancer, including: - Breast cancer - Colon cancer - Lung cancer - Pancreatic cancer - Gastric cancer - Renal cell carcinoma - Leukemias He noted that there is very little research on lymphomas, but that doesn’t mean it won’t work, it simply hasn’t been studied much yet. Important points from Dr. Makis: 1) The anti-cancer effect of Ivermectin appears to be dose dependent. 2) Higher doses may offer better results in more aggressive cancers. 3) For very aggressive cancers (such as pancreatic, leukemia, or brain cancers), he suggests considering 2 mg/kg or even up to 2.5 mg/kg per day. Some patients have used these higher doses for many months with only temporary side effects (such as mild visual disturbances that usually resolve within a few days). Real-world examples include a prostate cancer patient whose PSA dropped from 89 to 11 on 45 mg daily, and a terminal gallbladder cancer case that resolved after 14 months on 2 mg/kg. Dr. Makis emphasizes that Ivermectin is a very safe drug with no reported long-term side effects at 1 mg/kg. He recommends starting at this dose and adjusting upwards depending on the individual case and cancer type. He also stresses that people can safely stay on Ivermectin for months as long as there is active disease. If you're researching Ivermectin for cancer protocols, many people are choosing GENIX MEDS for clean, pharmaceutical-grade Ivermectin with straightforward worldwide delivery. #Ivermectindosage #MakisMD #Genixmeds

GENIX MEDS

20,168 次观看 • 2 个月前

IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary. Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only. Share to spread awareness — information. 📌 Save this protocol chart for future reference. 🔁 Share this with someone researching alternative or adjunctive cancer approaches Follow for more .
5:47

IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary. Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only. Share to spread awareness — information. 📌 Save this protocol chart for future reference. 🔁 Share this with someone researching alternative or adjunctive cancer approaches Follow for more .

Joe Tippens Protocol

45,836 次观看 • 11 天前

🚨IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION Based on Dr. William Makis MD's commonly shared dosing framework Thousands of people reference this ivermectin dosing chart. Below is a simplified breakdown organized by body weight (mg/kg per day). 📌LOW DOSE ≤ 0.5 mg/kg/day Best For: • Cancers in remission • Strong family history or genetic predisposition • Preventive (prophylactic) use Reported Side Effects: • No long-term side effects reported Example: Dr. Tess Lawrie reported a Stage 3 ovarian cancer patient who received chemotherapy plus 12 mg ivermectin daily. After 2 months, the tumor marker CA125 fell from 288 to 22, and the tumor was reported to have disappeared. 📌MEDIUM DOSE 1.0 mg/kg/day Best For: • Starting dose for many cancers including: • Lung cancer • Pancreatic cancer • Renal cell carcinoma • Gastric cancer Reported Side Effects: • No long-term side effects reported Example: Dr. Shankara Chetty reported a 70-year-old prostate cancer patient with a PSA of 89 taking 45 mg daily (along with lactoferrin). After 2 months, PSA reportedly decreased to 10.9. 📌HIGH DOSE 2.0 mg/kg/day Best For: • Aggressive cancers • Leukemia • Pancreatic cancer • Brain cancers Reported Side Effects: • No long-term side effects reported Example: Dr. Allan Landrito reported a Stage 4 gallbladder cancer patient taking 2 mg/kg daily for 14 months, with the cancer reportedly disappearing. 📌VERY HIGH DOSE ≥ 2.5 mg/kg/day Best For: • Extensive metastatic disease • Extremely poor prognosis • Certain aggressive brain cancers Possible Side Effects: • Temporary visual disturbances • Usually, short lived and resolve within days Example: Dr. Shankara Chetty reported using 2.5 mg/kg/day in a patient with no side effects reported. #Ivermectin #MakisMD #Genixmeds
5:47

🚨IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION Based on Dr. William Makis MD's commonly shared dosing framework Thousands of people reference this ivermectin dosing chart. Below is a simplified breakdown organized by body weight (mg/kg per day). 📌LOW DOSE ≤ 0.5 mg/kg/day Best For: • Cancers in remission • Strong family history or genetic predisposition • Preventive (prophylactic) use Reported Side Effects: • No long-term side effects reported Example: Dr. Tess Lawrie reported a Stage 3 ovarian cancer patient who received chemotherapy plus 12 mg ivermectin daily. After 2 months, the tumor marker CA125 fell from 288 to 22, and the tumor was reported to have disappeared. 📌MEDIUM DOSE 1.0 mg/kg/day Best For: • Starting dose for many cancers including: • Lung cancer • Pancreatic cancer • Renal cell carcinoma • Gastric cancer Reported Side Effects: • No long-term side effects reported Example: Dr. Shankara Chetty reported a 70-year-old prostate cancer patient with a PSA of 89 taking 45 mg daily (along with lactoferrin). After 2 months, PSA reportedly decreased to 10.9. 📌HIGH DOSE 2.0 mg/kg/day Best For: • Aggressive cancers • Leukemia • Pancreatic cancer • Brain cancers Reported Side Effects: • No long-term side effects reported Example: Dr. Allan Landrito reported a Stage 4 gallbladder cancer patient taking 2 mg/kg daily for 14 months, with the cancer reportedly disappearing. 📌VERY HIGH DOSE ≥ 2.5 mg/kg/day Best For: • Extensive metastatic disease • Extremely poor prognosis • Certain aggressive brain cancers Possible Side Effects: • Temporary visual disturbances • Usually, short lived and resolve within days Example: Dr. Shankara Chetty reported using 2.5 mg/kg/day in a patient with no side effects reported. #Ivermectin #MakisMD #Genixmeds

GENIX MEDS

31,415 次观看 • 3 个月前

Oncologist Dr. William Makis: "Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer...[and is] running, quietly, several clinical trials with mebendazole in cancer...So this is not fringe... There's... real science behind it, patents behind it." "For the past year and a half, I've been working with antiparasitics that are being repurposed for cancer. This is ivermectin, mebendazole and fenbendazole. And the reason is because there's a big body of research. There are over 400 published papers on ivermectin in cancer. There are over 240 published papers on mebendazole in cancer. "In fact, Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer, specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer. Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer. There's colon cancer, gastric cancer and brain cancer, including children, children with brain cancers as well. So this is not fringe, this is not, something that is far out. There's actually real science behind it, patents behind it. Dr. Sulack Pete "And when you search a lot of the AIs, for example Perplexity AI and you ask what are the most promising repurposed drugs for terminally ill cancer patients today, it will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole, there's other antiparasitics like hydroxychloroquine will be in the top 10, you will have curcumin in the top 10, you will have EGCG, which is from green tea extract in the top 10, resveratrol in the top 10, metformin, which is a diabetes drug but also has anti-cancer activity in the top 10 as well. "And what I have found working with these antiparasitics, is that there is a benefit to patients in at least 75% of the cases." Follow me for more Bombshell. #Fenbendazole #Ivermectin #Cancercure
3:49

Oncologist Dr. William Makis: "Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer...[and is] running, quietly, several clinical trials with mebendazole in cancer...So this is not fringe... There's... real science behind it, patents behind it." "For the past year and a half, I've been working with antiparasitics that are being repurposed for cancer. This is ivermectin, mebendazole and fenbendazole. And the reason is because there's a big body of research. There are over 400 published papers on ivermectin in cancer. There are over 240 published papers on mebendazole in cancer. "In fact, Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer, specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer. Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer. There's colon cancer, gastric cancer and brain cancer, including children, children with brain cancers as well. So this is not fringe, this is not, something that is far out. There's actually real science behind it, patents behind it. Dr. Sulack Pete "And when you search a lot of the AIs, for example Perplexity AI and you ask what are the most promising repurposed drugs for terminally ill cancer patients today, it will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole, there's other antiparasitics like hydroxychloroquine will be in the top 10, you will have curcumin in the top 10, you will have EGCG, which is from green tea extract in the top 10, resveratrol in the top 10, metformin, which is a diabetes drug but also has anti-cancer activity in the top 10 as well. "And what I have found working with these antiparasitics, is that there is a benefit to patients in at least 75% of the cases." Follow me for more Bombshell. #Fenbendazole #Ivermectin #Cancercure

Joe Tippens

46,807 次观看 • 2 个月前

100% Cancer Remission Achieved in ALL Patients of Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Andrea Cercek explained that it essentially unlocks the body’s ability to heal itself.
3:28

100% Cancer Remission Achieved in ALL Patients of Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Andrea Cercek explained that it essentially unlocks the body’s ability to heal itself.

The Vigilant Fox 🦊

2,528,122 次观看 • 2 年前

100% Cancer Remission Achieved in ALL Patients in Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Cercek explained that it essentially unlocks the body’s ability to heal itself.
3:28

100% Cancer Remission Achieved in ALL Patients in Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Cercek explained that it essentially unlocks the body’s ability to heal itself.

The Vigilant Fox 🦊

1,600,577 次观看 • 2 年前

Ivermectin and Mebendazole in Cancer Patients The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Overall, it is estimated that annual costs of standard chemotherapies average $111,000 per year. Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol. Methods: Prospective observational cohort of 197 cancer patients, who were prescribed ivermectin and mebendazole off-label through telemedicine (platform by licensed U.S. healthcare providers) Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. Data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) Results: Mean age of 67 years, (52.3% male, 47.7% female). Cancer types included Prostate 27.9% Breast 18.3% Lung 8.6% Colon 5.1% Urologic 4.6% Pancreatic 3.0% Liver 2.5% Gynaecologic 2.5% Hematologic 2.5% Median duration since initial diagnosis, 1.2 years 37.1% experiencing active disease progression. 6-month follow-up Medication adherence, 86.9% Full initial 90-capsule ivermectin-mebendazole prescription. The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Notably, 48.4% of cohort, strongest positive outcomes: Regression, 15.6% No current evidence of disease (NED), 32.8% Disease stability, 36.1% Disease progression, 15.6% No significant dose-response association was observed for cancer outcomes (p = 0.91), without a clear dose-response gradient for efficacy. Side effects Mild side effects (primarily gastrointestinal), 25.4% (93.6% of those affected continued treatment through minor dose adjustments) Concurrent conventional therapies Chemotherapy, 27.9% Radiation therapy, 21.3% Surgery, 19.7% Adjunctive interventions such as supplement use, 49.2% Dietary modification, 37.7% Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumours regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials Validate these observations and further define optimal dosing strategies. Mechanism (pharmacodynamics) Ivermectin and mebendazole are antiparasitic agents, demonstrated highly promising anti-cancer activity. Ivermectin Shown to exert over 14 distinct anti-cancer mechanisms across more than 12 cancer types, inhibiting cancer cell proliferation, metastasis, angiogenesis, mitochondrial function. Has demonstrated excellent safety in cancer patients (including those actively undergoing chemotherapy) Ivermectin and mebendazole selectively target cancer stem cells Mebendazole Microtubule disruption, leading to effective cell cycle arrest Potent induction of apoptosis Significant inhibition of tumour growth Inhibition of angiogenesis Disruption of glucose uptake When used together Target non-overlapping pathways, resulting in synergistic tumour regression, cancer stem cell depletion, and reversal of multidrug resistance in multiple in vitro and in vivo models Biodistribution, ivermectin and mebendazole document excellent tissue penetration
24:40

Ivermectin and Mebendazole in Cancer Patients The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Overall, it is estimated that annual costs of standard chemotherapies average $111,000 per year. Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol. Methods: Prospective observational cohort of 197 cancer patients, who were prescribed ivermectin and mebendazole off-label through telemedicine (platform by licensed U.S. healthcare providers) Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. Data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) Results: Mean age of 67 years, (52.3% male, 47.7% female). Cancer types included Prostate 27.9% Breast 18.3% Lung 8.6% Colon 5.1% Urologic 4.6% Pancreatic 3.0% Liver 2.5% Gynaecologic 2.5% Hematologic 2.5% Median duration since initial diagnosis, 1.2 years 37.1% experiencing active disease progression. 6-month follow-up Medication adherence, 86.9% Full initial 90-capsule ivermectin-mebendazole prescription. The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Notably, 48.4% of cohort, strongest positive outcomes: Regression, 15.6% No current evidence of disease (NED), 32.8% Disease stability, 36.1% Disease progression, 15.6% No significant dose-response association was observed for cancer outcomes (p = 0.91), without a clear dose-response gradient for efficacy. Side effects Mild side effects (primarily gastrointestinal), 25.4% (93.6% of those affected continued treatment through minor dose adjustments) Concurrent conventional therapies Chemotherapy, 27.9% Radiation therapy, 21.3% Surgery, 19.7% Adjunctive interventions such as supplement use, 49.2% Dietary modification, 37.7% Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumours regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials Validate these observations and further define optimal dosing strategies. Mechanism (pharmacodynamics) Ivermectin and mebendazole are antiparasitic agents, demonstrated highly promising anti-cancer activity. Ivermectin Shown to exert over 14 distinct anti-cancer mechanisms across more than 12 cancer types, inhibiting cancer cell proliferation, metastasis, angiogenesis, mitochondrial function. Has demonstrated excellent safety in cancer patients (including those actively undergoing chemotherapy) Ivermectin and mebendazole selectively target cancer stem cells Mebendazole Microtubule disruption, leading to effective cell cycle arrest Potent induction of apoptosis Significant inhibition of tumour growth Inhibition of angiogenesis Disruption of glucose uptake When used together Target non-overlapping pathways, resulting in synergistic tumour regression, cancer stem cell depletion, and reversal of multidrug resistance in multiple in vitro and in vivo models Biodistribution, ivermectin and mebendazole document excellent tissue penetration

Dr. Zakaria MD

10,766 次观看 • 2 个月前

IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary. Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only. Share to spread awareness — information is power. 💊
5:47

IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary. Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only. Share to spread awareness — information is power. 💊

Valerie Anne Smith

970,332 次观看 • 4 个月前

IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary. Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only. Share to spread awareness — information is power. 💊
5:47

IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary. Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only. Share to spread awareness — information is power. 💊

Joe Tippens

136,304 次观看 • 2 个月前

IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary. Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only. Share to spread awareness — information. Follow for more .
1:00

IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary. Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only. Share to spread awareness — information. Follow for more .

mcgill_medicines

105,936 次观看 • 1 个月前

🚨 #BREAKING: New PubMed peer reviewed study shows 84% of cancer patients taking ivermectin + mebendazole disappeared, shrunk, or stopped spreading after several months 🔻 The Study and Important Caveats: Researchers followed 197 cancer patients who took a combination of ivermectin and mebendazole (off-label, through a telemedicine service). After 6 months, 122 of them filled out a follow-up survey. Among those 122 people: 84% said their cancer had either completely disappeared, shrunk, or stopped spreading. About 33% reported “no evidence of disease” About 16% reported the tumors got smaller About 36% said the cancer stayed the same (stable) 16% said it got worse Side effects were mostly mild (mainly stomach issues) and most people kept taking the medicine. 🔻 Important caveats: • The results come only from patient surveys — no doctors independently checked scans or medical records. • There was no control group to compare against. • Many patients were also getting regular cancer treatments (chemo, radiation, surgery, etc.) at the same time. • About 38% of the original group didn’t finish the survey. • The journal later issued an official “Expression of Concern” and started an audit because of questions about the data. • The authors say these findings are just a starting point and that proper clinical trials are still needed. 🔻What kinds of cancer were included? Most common Prostate: 55 patients (27.9%) Breast: 36 patients (18.3%) Lung: 17 patients (8.6%) Colon: 10 patients (5.1%) Liver: 5 patients (2.5%) Other cancers (74 patients / 37.6%) Urologic (bladder & kidney): 9 Pancreatic & bile duct: 6 Hematologic (lymphoma): 5 Head, neck & oral: 5 Gynecologic (ovarian & uterine): 5 Thyroid: 4 Brain & neurological: 3 Multiple myeloma: 3 Melanoma (skin & ocular): 3 Sarcoma: 2 Miscellaneous/unspecified: 29 🔻Final Note: The study does not show which cancers benefited the most. All the results (including the 84% figure) are reported only as overall numbers. Clip Study
0:33

🚨 #BREAKING: New PubMed peer reviewed study shows 84% of cancer patients taking ivermectin + mebendazole disappeared, shrunk, or stopped spreading after several months 🔻 The Study and Important Caveats: Researchers followed 197 cancer patients who took a combination of ivermectin and mebendazole (off-label, through a telemedicine service). After 6 months, 122 of them filled out a follow-up survey. Among those 122 people: 84% said their cancer had either completely disappeared, shrunk, or stopped spreading. About 33% reported “no evidence of disease” About 16% reported the tumors got smaller About 36% said the cancer stayed the same (stable) 16% said it got worse Side effects were mostly mild (mainly stomach issues) and most people kept taking the medicine. 🔻 Important caveats: • The results come only from patient surveys — no doctors independently checked scans or medical records. • There was no control group to compare against. • Many patients were also getting regular cancer treatments (chemo, radiation, surgery, etc.) at the same time. • About 38% of the original group didn’t finish the survey. • The journal later issued an official “Expression of Concern” and started an audit because of questions about the data. • The authors say these findings are just a starting point and that proper clinical trials are still needed. 🔻What kinds of cancer were included? Most common Prostate: 55 patients (27.9%) Breast: 36 patients (18.3%) Lung: 17 patients (8.6%) Colon: 10 patients (5.1%) Liver: 5 patients (2.5%) Other cancers (74 patients / 37.6%) Urologic (bladder & kidney): 9 Pancreatic & bile duct: 6 Hematologic (lymphoma): 5 Head, neck & oral: 5 Gynecologic (ovarian & uterine): 5 Thyroid: 4 Brain & neurological: 3 Multiple myeloma: 3 Melanoma (skin & ocular): 3 Sarcoma: 2 Miscellaneous/unspecified: 29 🔻Final Note: The study does not show which cancers benefited the most. All the results (including the 84% figure) are reported only as overall numbers. Clip Study

MJTruthUltra

29,659 次观看 • 27 天前

100% Cancer Remission Achieved in ALL Patients in Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Andrea Cercek explained that it essentially unlocks the body’s ability to heal itself. Watch the breakdown of this study in the comment below.
2:18

100% Cancer Remission Achieved in ALL Patients in Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Andrea Cercek explained that it essentially unlocks the body’s ability to heal itself. Watch the breakdown of this study in the comment below.

The Vigilant Fox 🦊

1,690,255 次观看 • 2 年前

Oncologist Dr. William Makis: "Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer...[and is] running, quietly, several clinical trials with mebendazole in cancer...So this is not fringe... There's... real science behind it, patents behind it." This clip of Dr. Makis (William Makis), a radiologist, oncologist, and cancer researcher, is taken from an interview with Seth Holehouse () posted to Rumble on November 21, 2025. ----------------Partial transcription of clip--------------- "For the past year and a half, I've been working with antiparasitics that are being repurposed for cancer. This is ivermectin, mebendazole and fenbendazole. And the reason is because there's a big body of research. There are over 400 published papers on ivermectin in cancer. There are over 240 published papers on mebendazole in cancer. "In fact, Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer, specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer. Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer. There's colon cancer, gastric cancer and brain cancer, including children, children with brain cancers as well. So this is not fringe, this is not, something that is far out. There's actually real science behind it, patents behind it. "And when you search a lot of the AIs, for example Perplexity AI and you ask what are the most promising repurposed drugs for terminally ill cancer patients today, it will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole, there's other antiparasitics like hydroxychloroquine will be in the top 10, you will have curcumin in the top 10, you will have EGCG, which is from green tea extract in the top 10, resveratrol in the top 10, metformin, which is a diabetes drug but also has anti-cancer activity in the top 10 as well. "And what I have found working with these antiparasitics, is that there is a benefit to patients in at least 75% of the cases."
1:59

Oncologist Dr. William Makis: "Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer...[and is] running, quietly, several clinical trials with mebendazole in cancer...So this is not fringe... There's... real science behind it, patents behind it." This clip of Dr. Makis (William Makis), a radiologist, oncologist, and cancer researcher, is taken from an interview with Seth Holehouse () posted to Rumble on November 21, 2025. ----------------Partial transcription of clip--------------- "For the past year and a half, I've been working with antiparasitics that are being repurposed for cancer. This is ivermectin, mebendazole and fenbendazole. And the reason is because there's a big body of research. There are over 400 published papers on ivermectin in cancer. There are over 240 published papers on mebendazole in cancer. "In fact, Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer, specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer. Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer. There's colon cancer, gastric cancer and brain cancer, including children, children with brain cancers as well. So this is not fringe, this is not, something that is far out. There's actually real science behind it, patents behind it. "And when you search a lot of the AIs, for example Perplexity AI and you ask what are the most promising repurposed drugs for terminally ill cancer patients today, it will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole, there's other antiparasitics like hydroxychloroquine will be in the top 10, you will have curcumin in the top 10, you will have EGCG, which is from green tea extract in the top 10, resveratrol in the top 10, metformin, which is a diabetes drug but also has anti-cancer activity in the top 10 as well. "And what I have found working with these antiparasitics, is that there is a benefit to patients in at least 75% of the cases."

Sense Receptor

228,635 次观看 • 9 个月前

🚨 CANCER GONE — THE STORY BIG PHARMA NEVER WANTED YOU TO HEAR 🚨 Dr. Mark Gordon just revealed something STUNNING: A 76-year-old U.S. Veteran — fighting prostate cancer — entered a trial using Ivermectin. → 12mg per day. → 8 weeks of treatment. → No chemotherapy. No radiation. And after 12 weeks? 💥 NO DETECTABLE CANCER. Gone. Just like that. 📢 WHAT THIS MEANS: → The same Ivermectin they mocked. → The same Ivermectin they banned. → The same Ivermectin that threatened Big Pharma's trillion-dollar narrative. Turns out? It wasn’t just about COVID. It was about CONTROL. Imagine a world where cheap, safe, off-patent drugs could treat cancer. Imagine the profits lost. Imagine the lies needed to bury that truth. They called it “horse paste.” Now? They’re speechless. Ivermectin didn’t just save lives. 💥 IT MAY HAVE SAVED THIS MAN FROM CANCER. This is why truth matters. This is why censorship kills. This is why they’re TERRIFIED. Joe Rogan
0:53

🚨 CANCER GONE — THE STORY BIG PHARMA NEVER WANTED YOU TO HEAR 🚨 Dr. Mark Gordon just revealed something STUNNING: A 76-year-old U.S. Veteran — fighting prostate cancer — entered a trial using Ivermectin. → 12mg per day. → 8 weeks of treatment. → No chemotherapy. No radiation. And after 12 weeks? 💥 NO DETECTABLE CANCER. Gone. Just like that. 📢 WHAT THIS MEANS: → The same Ivermectin they mocked. → The same Ivermectin they banned. → The same Ivermectin that threatened Big Pharma's trillion-dollar narrative. Turns out? It wasn’t just about COVID. It was about CONTROL. Imagine a world where cheap, safe, off-patent drugs could treat cancer. Imagine the profits lost. Imagine the lies needed to bury that truth. They called it “horse paste.” Now? They’re speechless. Ivermectin didn’t just save lives. 💥 IT MAY HAVE SAVED THIS MAN FROM CANCER. This is why truth matters. This is why censorship kills. This is why they’re TERRIFIED. Joe Rogan

skymeds store | Online Ivermectin Pharmacy

185,281 次观看 • 11 个月前